Kenvue Inc. $KVUE Holdings Raised by Blair William & Co. IL

Key Points

• Blair William & Co. IL increased its stake in Kenvue Inc. (KVUE) by 17.7% during the 2nd quarter, now owning 206,387 shares valued at approximately $4.32 million.
• Kenvue reported $0.29 earnings per share for the latest quarter, slightly exceeding analysts' expectations, but its revenue declined 4.0% year-over-year.
• The company recently declared a quarterly dividend of $0.2075 per share, reflecting a boost from the previous dividend and resulting in an annualized yield of 5.0%.

Blair William & Co. IL grew its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 17.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 206,387 shares of the company's stock after purchasing an additional 31,088 shares during the period. Blair William & Co. IL's holdings in Kenvue were worth $4,320,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue during the first quarter valued at $30,000. Trust Co. of Vermont lifted its stake in Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock worth $33,000 after acquiring an additional 1,150 shares in the last quarter. TruNorth Capital Management LLC purchased a new stake in Kenvue in the 1st quarter worth about $36,000. Truvestments Capital LLC purchased a new stake in Kenvue in the 1st quarter worth about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd lifted its stake in Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after acquiring an additional 1,287 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Down 1.0%

KVUE opened at $16.68 on Monday. Kenvue Inc. has a fifty-two week low of $15.47 and a fifty-two week high of $25.17. The business has a 50-day moving average of $19.15 and a 200-day moving average of $21.31. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The company has a market capitalization of $32.00 billion, a PE ratio of 22.53, a price-to-earnings-growth ratio of 2.39 and a beta of 0.72.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same period last year, the business earned $0.32 EPS. The business's quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.0%. Kenvue's dividend payout ratio (DPR) is 112.16%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several research analyst reports. Weiss Ratings reissued a "hold (c)" rating on shares of Kenvue in a research note on Saturday, September 27th. Bank of America reduced their price objective on Kenvue from $25.00 to $21.00 and set a "buy" rating for the company in a research note on Wednesday, October 8th. Rothschild & Co Redburn raised Kenvue from a "neutral" rating to a "buy" rating and reduced their price objective for the stock from $22.50 to $22.00 in a research note on Friday, September 26th. Evercore ISI reduced their price objective on Kenvue from $23.00 to $18.00 and set an "in-line" rating for the company in a research note on Tuesday, September 23rd. Finally, Royal Bank Of Canada reduced their price objective on Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $21.18.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.